MultiValent Biotherapies
PrivateLast Round
Series A
Jun 16, 2026
Total Funding Raised
$27.43M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
MultiValent Biotherapies, Inc. is a biotechnology company developing targeted drug conjugate therapies for cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
MultiValent Biotherapies Comparables
Compare MultiValent Biotherapies with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Coherent Biopharma | 83% | |
| Tianjin Conjustar Biotechnology Co., Ltd. | 78% | |
| Eli Lilly and Company | 77% |
MultiValent Biotherapies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jun 16, 2026 |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 16, 2026
$27M round led by Coherent Biopharma
MultiValent Biotherapies Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about MultiValent Biotherapies's valuation, stock price, and market status.
Is MultiValent Biotherapies a public or private company?
MultiValent Biotherapies is a private company.
What is the current stock price of MultiValent Biotherapies?
MultiValent Biotherapies is a private company with no public stock price. No recent secondary market data is available.
How much is MultiValent Biotherapies worth (valuation)?
Valuation information for MultiValent Biotherapies is not publicly available.
Can I buy MultiValent Biotherapies stock?
MultiValent Biotherapies shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was MultiValent Biotherapies's last funding round?
MultiValent Biotherapies's most recent funding round was Series A on June 16, 2026.
Who are the main investors in MultiValent Biotherapies?
Investor information for MultiValent Biotherapies is not publicly disclosed.
Will MultiValent Biotherapies IPO soon?
No public IPO plans have been announced for MultiValent Biotherapies.
How can I track MultiValent Biotherapies secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor MultiValent Biotherapies's secondary market activity and sign up for updates.